Non-HFE hemochromatosis: Pathophysiological and diagnostic aspects

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 2, 2014, Pages 143-154

  Bardou Jacquet, Edouard ^a,b   Ben Ali, Zeineb ^a   Beaumont Epinette, Marie Pascale ^a   Loreal, Olivier ^a,b   Jouanolle, Anne Marie ^a   Brissot, Pierre ^a,b  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; FERRITIN; FERROPORTIN; HEMOJUVELIN; HEPCIDIN; TRANSFERRIN; TRANSFERRIN RECEPTOR 2; BENZOIC ACID DERIVATIVE; CATION TRANSPORT PROTEIN; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; IRON; IRON CHELATING AGENT; MEMBRANE PROTEIN; METAL TRANSPORTING PROTEIN 1; TFR2 PROTEIN, HUMAN; TRANSFERRIN RECEPTOR; TRIAZOLE DERIVATIVE;

ALCOHOL CONSUMPTION; CHELATION THERAPY; CLINICAL FEATURE; CONGENITAL CATARACT; DECISION TREE; DIAGNOSTIC TEST; DIET THERAPY; FAMILY; FERRITIN BLOOD LEVEL; GAUCHER DISEASE; GENE MUTATION; GENETIC IDENTIFICATION; GENETIC SCREENING; HEMOCHROMATOSIS; HEMOCHROMATOSIS TYPE 1; HEMOCHROMATOSIS TYPE 2A; HEMOCHROMATOSIS TYPE 2B; HEMOCHROMATOSIS TYPE 3; HEMOCHROMATOSIS TYPE 4A; HEMOCHROMATOSIS TYPE 4B; HEREDITARY HYPERFERRITINEMIA CATARACT SYNDROME; HORMONE DEFICIENCY; HUMAN; HYPERFERRITINEMIA; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; LIVER INJURY; MACROPHAGE ACTIVATION SYNDROME; METABOLIC SYNDROME X; NON HFE HEMOCHROMATOSIS; PATHOPHYSIOLOGY; PATIENT REFERRAL; PHLEBOTOMY; SHORT SURVEY; BIOPSY; CATARACT; DEFICIENCY; DIET; DRINKING BEHAVIOR; GENETICS; INFLAMMATION; IRON METABOLISM DISORDERS; LIVER; METABOLISM; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY;

ALCOHOL DRINKING; BENZOATES; BIOPSY; CATARACT; CATION TRANSPORT PROTEINS; DECISION TREES; DIET; GAUCHER DISEASE; GENETIC TESTING; HEMOCHROMATOSIS; HEPCIDINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INFLAMMATION; IRON; IRON CHELATING AGENTS; IRON METABOLISM DISORDERS; IRON OVERLOAD; LIVER; MACROPHAGE ACTIVATION SYNDROME; MAGNETIC RESONANCE IMAGING; MEMBRANE PROTEINS; METABOLIC SYNDROME X; MUTATION; PHLEBOTOMY; RECEPTORS, TRANSFERRIN; TRANSFERRIN; TRIAZOLES;

EID: 84899484234     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.11.003     Document Type: Short Survey

References (144)

1. Simon M., Bourel M., Genetet B., Fauchet R. Idiopathic hemochromatosis. Demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med 1977, 297:1017-1021.
2. Feder J.N., Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13:399-408.
3. Krause A., Neitz S., Magert H.J., et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000, 480:147-150.
4. Pigeon C., Ilyin G., Courselaud B., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001, 276:7811-7819.
5. Nicolas G., Bennoun M., Devaux I., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001, 98:8780-8785.
6. Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001, 276:7806-7810.
7. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011, 117:4425-4433.
8. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
9. Gao J., Chen J., Kramer M., Tsukamoto H., Zhang A.S., Enns C.A. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009, 9:217-227.
10. Corradini E., Rozier M., Meynard D., et al. Iron regulation of hepcidin despite attenuated Smad1,5,8 signaling in mice without transferrin receptor 2 or Hfe. Gastroenterology 2011, 141:1907-1914.
11. Andriopoulos B., Corradini E., Xia Y., et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009, 41:482-487.
12. Babitt J.L., Huang F.W., Wrighting D.M., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006, 38:531-539.
13. Babitt J.L., Huang F.W., Xia Y., Sidis Y., Andrews N.C., Lin H.Y. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007, 117:1933-1939.
14. Shayeghi M., Latunde-Dada G.O., Oakhill J.S., et al. Identification of an intestinal heme transporter. Cell 2005, 122:789-801.
15. Gunshin H., Fujiwara Y., Custodio A.O., Direnzo C., Robine S., Andrews N.C. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest 2005, 115:1258-1266.
16. Abboud S., Haile D.J. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000, 275:19906-19912.
17. McKie A.T., Marciani P., Rolfs A., et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000, 5:299-309.
18. Donovan A., Brownlie A., Zhou Y., et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000, 403:776-781.
19. Vulpe C.D., Kuo Y.M., Murphy T.L., et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 1999, 21:195-199.
20. Bekri S., Gual P., Anty R., et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006, 131:788-796.
21. Peyssonnaux C., Zinkernagel A.S., Datta V., Lauth X., Johnson R.S., Nizet V. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 2006, 107:3727-3732.
22. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101:2461-2463.
23. Nicolas G., Viatte L., Bennoun M., Beaumont C., Kahn A., Vaulont S. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 2002, 29:327-335.
24. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 2007, 18:394-400.
25. Rivera S., Nemeth E., Gabayan V., Lopez M.A., Farshidi D., Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 2005, 106:2196-2199.
26. Courselaud B., Pigeon C., Inoue Y., et al. C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem 2002, 277:41163-41170.
27. Fatih N., Camberlein E., Island M.L., et al. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J Mol Med (Berl) 2010, 88:477-486.
28. Pietrangelo A., Dierssen U., Valli L., et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 2007, 132:294-300.
29. Verga Falzacappa M.V., Vujic Spasic M., Kessler R., Stolte J., Hentze M.W., Muckenthaler M.U. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007, 109:353-358.
30. Wrighting D.M., Andrews N.C. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006, 108:3204-3209.
31. Truksa J., Peng H., Lee P., Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci U S A 2006, 103:10289-10293.
32. Wang R.H., Li C., Xu X., et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005, 2:399-409.
33. Steinbicker A.U., Bartnikas T.B., Lohmeyer L.K., et al. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood 2011, 118:4224-4230.
34. Kautz L., Meynard D., Monnier A., et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 2008, 112:1503-1509.
35. Meynard D., Kautz L., Darnaud V., Canonne-Hergaux F., Coppin H., Roth M.P. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009, 41:478-481.
36. Ramos E., Kautz L., Rodriguez R., et al. Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology 2011, 53:1333-1341.
37. D'Alessio F., Hentze M.W., Muckenthaler M.U. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation. J Hepatol 2012, 57:1052-1060.
38. Wallace D.F., Summerville L., Crampton E.M., Frazer D.M., Anderson G.J., Subramaniam V.N. Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload. Hepatology 2009, 50:1992-2000.
39. Schmidt P.J., Fleming M.D. Transgenic HFE-dependent induction of hepcidin in mice does not require transferrin receptor-2. Am J Hematol 2012, 87:588-595.
40. Goswami T., Andrews N.C. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 2006, 281:28494-28498.
41. Johnson M.B., Enns C.A. Diferric transferrin regulates transferrin receptor 2 protein stability. Blood 2004, 104:4287-4293.
42. Calzolari A., Raggi C., Deaglio S., et al. TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci 2006, 119:4486-4498.
43. Valore E.V., Ganz T. Post-translational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis 2008, 40:132-138.
44. Silvestri L., Pagani A., Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008, 111:924-931.
45. Garuti C., Tian Y., Montosi G., et al. Hepcidin expression does not rescue the iron-poor phenotype of Kupffer cells in Hfe-null mice after liver transplantation. Gastroenterology 2010, 139:315e1-322e1.
46. Bardou-Jacquet E., Philip J., Lorho R., et al. Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis. Hepatology 2013, [Epub ahead of print]. 10.1002/hep.26570.
47. Papanikolaou G., Tzilianos M., Christakis J.I., et al. Hepcidin in iron overload disorders. Blood 2005, 105:4103-4105.
48. Hershko C., Graham G., Bates G.W., Rachmilewitz E.A. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978, 40:255-263.
49. Hider R.C. Nature of nontransferrin-bound iron. Eur J Clin Invest 2002, 32(Suppl 1):50-54.
50. Brissot P., Wright T.L., Ma W.L., Weisiger R.A. Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 1985, 76:1463-1470.
51. Esposito B.P., Breuer W., Sirankapracha P., Pootrakul P., Hershko C., Cabantchik Z.I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003, 102:2670-2677.
52. Le Lan C., Loreal O., Cohen T., et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005, 105:4527-4531.
53. De Domenico I., Ward D.M., Musci G., Kaplan J. Iron overload due to mutations in ferroportin. Haematologica 2006, 91:92-95.
54. Drakesmith H., Schimanski L.M., Ormerod E., et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 2005, 106:1092-1097.
55. De Domenico I., Ward D.M., di Patti M.C., et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. Embo J 2007, 26:2823-2831.
56. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007, 46:1291-1301.
57. Piperno A., Girelli D., Nemeth E., et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood 2007, 110:4096-4100.
58. Loreal O., Haziza-Pigeon C., Troadec M.B., et al. Hepcidin in iron metabolism. Curr Protein Pept Sci 2005, 6:279-291.
59. Detivaud L., Nemeth E., Boudjema K., et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 2005, 106:746-748.
60. Babitt J.L., Lin H.Y. The molecular pathogenesis of hereditary hemochromatosis. Semin Liver Dis 2011, 31:280-292.
61. Murphy A.T., Witcher D.R., Luan P., Wroblewski V.J. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood 2007, 110:1048-1054.
62. Jouanolle A.M., Fergelot P., Gandon G., Yaouanq J., Le Gall J.Y., David V. A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. Hum Genet 1997, 100:544-547.
63. Adams P.C., Reboussin D.M., Barton J.C., et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005, 352:1769-1778.
64. Deugnier Y., Jouanolle A.M., Chaperon J., et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br J Haematol 2002, 118:1170-1178.
65. Merryweather-Clarke A.T., Pointon J.J., Shearman J.D., Robson K.J. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997, 34:275-278.
66. Gochee P.A., Powell L.W., Cullen D.J., Du Sart D., Rossi E., Olynyk J.K. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002, 122:646-651.
67. Walsh A., Dixon J.L., Ramm G.A., et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006, 4:1403-1410.
68. EASL EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010, 53:3-22.
69. Bacon B.R., Adams P.C., Kowdley K.V., Powell L.W., Tavill A.S. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:328-343.
70. Aguilar-Martinez P., Grandchamp B., Cunat S., et al. Iron overload in HFE C282Y heterozygotes at first genetic testing: a strategy for identifying rare HFE variants. Haematologica 2011, 96:507-514.
71. Beutler E., Felitti V.J., Koziol J.A., Ho N.J., Gelbart T. Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002, 359:211-218.
72. Olynyk J.K., Cullen D.J., Aquilia S., Rossi E., Summerville L., Powell L.W. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999, 341:718-724.
73. Waalen J., Nordestgaard B.G., Beutler E. The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol 2005, 18:203-220.
74. Allen K.J., Gurrin L.C., Constantine C.C., et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008, 358:221-230.
75. van der A.D., Peeters P.H., Grobbee D.E., Roest M., Voorbij H.A., van der Schouw Y.T. HFE genotypes and dietary heme iron: no evidence of strong gene-nutrient interaction on serum ferritin concentrations in middle-aged women. Nutr Metab Cardiovasc Dis 2006, 16:60-68.
76. Kaltwasser J.P., Werner E., Schalk K., Hansen C., Gottschalk R., Seidl C. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 1998, 43:699-704.
77. Loreal O., Deugnier Y., Moirand R., et al. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J Hepatol 1992, 16:122-127.
78. Bridle K., Cheung T.K., Murphy T., et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 2006, 30:106-112.
79. Desgrippes R., Laine F., Morcet J., et al. Decreased iron burden in overweight C282Y homozygous women: putative role of increased hepcidin production. Hepatology 2013, 57:1784-1792.
80. Laine F., Jouannolle A.M., Morcet J., et al. Phenotypic expression in detected C282Y homozygous women depends on body mass index. J Hepatol 2005, 43:1055-1059.
81. Moirand R., Adams P.C., Bicheler V., Brissot P., Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med 1997, 127:105-110.
82. Levy J.E., Montross L.K., Andrews N.C. Genes that modify the hemochromatosis phenotype in mice. J Clin Invest 2000, 105:1209-1216.
83. Bensaid M., Fruchon S., Mazeres C., Bahram S., Roth M.P., Coppin H. Multigenic control of hepatic iron loading in a murine model of hemochromatosis. Gastroenterology 2004, 126:1400-1408.
84. Tolosano E., Fagoonee S., Garuti C., et al. Haptoglobin modifies the hemochromatosis phenotype in mice. Blood 2005, 105:3353-3355.
85. Jacolot S., Le Gac G., Scotet V., Quere I., Mura C., Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004, 103:2835-2840.
86. Merryweather-Clarke A.T., Cadet E., Bomford A., et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003, 12:2241-2247.
87. Le Gac G., Scotet V., Ka C., et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 2004, 13:1913-1918.
88. Milet J., Dehais V., Bourgain C., et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am J Hum Genet 2007, 81:799-807.
89. Lee P., Gelbart T., West C., Halloran C., Beutler E. Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol Dis 2002, 29:471-487.
90. Lamon J.M., Marynick S.P., Roseblatt R., Donnelly S. Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people. Gastroenterology 1979, 76:178-183.
91. Papanikolaou G., Samuels M.E., Ludwig E.H., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004, 36:77-82.
92. Roetto A., Papanikolaou G., Politou M., et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003, 33:21-22.
93. Gkouvatsos K., Wagner J., Papanikolaou G., Sebastiani G., Pantopoulos K. Conditional disruption of mouse HFE2 gene: maintenance of systemic iron homeostasis requires hepatic but not skeletal muscle hemojuvelin. Hepatology 2011, 54:1800-1807.
94. Island M.L., Jouanolle A.M., Mosser A., et al. A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis. Haematologica 2009, 94:720-724.
95. Hsiao P.J., Tsai K.B., Shin S.J., et al. A novel mutation of transferrin receptor 2 in a Taiwanese woman with type 3 hemochromatosis. J Hepatol 2007, 47:303-306.
96. Le Gac G., Mons F., Jacolot S., Scotet V., Ferec C., Frebourg T. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br J Haematol 2004, 125:674-678.
97. Majore S., Milano F., Binni F., et al. Homozygous p.M172K mutation of the TFR2 gene in an Italian family with type 3 hereditary hemochromatosis and early onset iron overload. Haematologica 2006, 91:ECR33.
98. Piperno A., Roetto A., Mariani R., et al. Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica 2004, 89:359-360.
99. Roetto A., Totaro A., Piperno A., et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001, 97:2555-2560.
100. Bardou-Jacquet E., Cunat S., Beaumont-Epinette M.P., et al. Variable age of onset and clinical severity in transferrin receptor 2 related haemochromatosis: novel observations. Br J Haematol 2013, 162:278-281.
101. Girelli D., Bozzini C., Roetto A., et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 2002, 122:1295-1302.
102. Gerolami V., Le Gac G., Mercier L., Nezri M., Berge-Lefranc J.L., Ferec C. Early-onset haemochromatosis caused by a novel combination of TFR2 mutations(p.R396X/c.1538-2 A>G) in a woman of Italian descent. Haematologica 2008, 93:e45-e46.
103. Montosi G., Donovan A., Totaro A., et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001, 108:619-623.
104. Njajou O.T., Vaessen N., Joosse M., et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001, 28:213-214.
105. Barton J.C., Acton R.T., Lee P.L., West C. SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent. Blood Cells Mol Dis 2007, 39:206-211.
106. Beutler E., Barton J.C., Felitti V.J., et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003, 31:305-309.
107. Subramaniam V.N., Wallace D.F., Dixon J.L., Fletcher L.M., Crawford D.H. Ferroportin disease due to the A77D mutation in Australia. Gut 2005, 54:1048-1049.
108. Le Lan C., Mosser A., Ropert M., et al. Sex and acquired cofactors determine phenotypes of ferroportin disease. Gastroenterology 2011, 140:1199e1-1207e1.
109. Wallace D.F., Clark R.M., Harley H.A., Subramaniam V.N. Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis. J Hepatol 2004, 40:710-713.
110. Sham R.L., Phatak P.D., West C., Lee P., Andrews C., Beutler E. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis 2005, 34:157-161.
111. Miyajima H., Takahashi Y., Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 2003, 16:205-213.
112. Yoshida K., Furihata K., Takeda S., et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995, 9:267-272.
113. Kono S., Suzuki H., Takahashi K., et al. Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia. Gastroenterology 2006, 131:240-245.
114. Knisely A.S., Gelbart T., Beutler E. Molecular characterization of a third case of human atransferrinemia. Blood 2004, 104:2607.
115. Mims M.P., Guan Y., Pospisilova D., et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 2005, 105:1337-1342.
116. Beaumont C., Delaunay J., Hetet G., Grandchamp B., de Montalembert M., Tchernia G. Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload. Blood 2006, 107:4168-4170.
117. Iolascon A., d'Apolito M., Servedio V., Cimmino F., Piga A., Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood 2006, 107:349-354.
118. Bardou-Jacquet E., Island M.L., Jouanolle A.M., et al. A novel N491S mutation in the human SLC11A2 gene impairs protein trafficking and in association with the G212V mutation leads to microcytic anemia and liver iron overload. Blood Cells Mol Dis 2011, 47:243-248.
119. Cox T.C., Bottomley S.S., Wiley J.S., Bawden M.J., Matthews C.S., May B.K. X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N Engl J Med 1994, 330:675-679.
120. Allikmets R., Raskind W.H., Hutchinson A., Schueck N.D., Dean M., Koeller D.M. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet 1999, 8:743-749.
121. Camaschella C., Campanella A., De Falco L., et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 2007, 110:1353-1358.
122. Moirand R., Kerdavid F., Loreal O., et al. Regulation of ferritin expression by alcohol in a human hepatoblastoma cell line and in rat hepatocyte cultures. J Hepatol 1995, 23:431-439.
123. Eckel R.H., Alberti K.G., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2010, 375:181-183.
124. Mendler M.H., Turlin B., Moirand R., et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999, 117:1155-1163.
125. Ruivard M., Laine F., Ganz T., et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 2009, 50:1219-1225.
126. Ferrante M., Geubel A.P., Fevery J., Marogy G., Horsmans Y., Nevens F. Hereditary hyperferritinaemia-cataract syndrome: a challenging diagnosis for the hepatogastroenterologist. Eur J Gastroenterol Hepatol 2005, 17:1247-1253.
127. Kannengiesser C., Jouanolle A.M., Hetet G., et al. A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica 2009, 94:335-339.
128. Girelli D., Bozzini C., Zecchina G., et al. Clinical, biochemical and molecular findings in a series of families with hereditary hyperferritinaemia-cataract syndrome. Br J Haematol 2001, 115:334-340.
129. Gandon Y., Olivie D., Guyader D., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004, 363:357-362.
130. St Pierre T.G., Clark P.R., Chua-anusorn W., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005, 105:855-861.
131. Pietrangelo A., Corradini E., Ferrara F., et al. Magnetic resonance imaging to identify classic and non-classic forms of ferroportin disease. Blood Cells Mol Dis 2006, 37:192-196.
132. Wood J.C., Enriquez C., Ghugre N., et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005, 106:1460-1465.
133. Deugnier Y., Turlin B. Pathology of hepatic iron overload. World J Gastroenterol 2007, 13:4755-4760.
134. Deugnier Y., Turlin B. Pathology of hepatic iron overload. Semin Liver Dis 2011, 31:260-271.
135. Stauber R.E., Lackner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 2007, 13:4287-4294.
136. Crawford D.H., Murphy T.L., Ramm L.E., et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 2009, 49:418-425.
137. Barton J.C., Lee P.L., West C., Bottomley S.S. Iron overload and prolonged ingestion of iron supplements: clinical features and mutation analysis of hemochromatosis-associated genes in four cases. Am J Hematol 2006, 81:760-767.
138. Deugnier Y., Loreal O., Carre F., et al. Increased body iron stores in elite road cyclists. Med Sci Sports Exerc 2002, 34:876-880.
139. Tanno T., Bhanu N.V., Oneal P.A., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007, 13:1096-1101.
140. Musallam K.M., Rivella S., Vichinsky E., Rachmilewitz E.A. Non-transfusion-dependent thalassemias. Haematologica 2013, 98:833-844.
141. Dale J.C., Burritt M.F., Zinsmeister A.R. Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels. Am J Clin Pathol 2002, 117:802-808.
142. Adams P.C., Reboussin D.M., Press R.D., et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med 2007, 120:999e1-999e7.
143. EASL. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010, 53:3-22.
144. Phatak P., Brissot P., Wurster M., et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010, 52:1671-1779.